Cellular therapy in Tuberculosis. (March 2015)

• Record Type: Journal Article
• Authors: Parida, Shreemanta K.; Madansein, Rajhmun; Singh, Nalini; Padayatchi, Nesri; Master, Iqbal; Naidu, Kantharuben; Zumla, Alimuddin; Maeurer, Markus
• Is Part Of: International journal of infectious diseases. Volume 32(2015:Mar.)
• Page Start: 32
• Page End: 38
• Publication Date: 2015-03
• Subjects: Tuberculosis -- MDR-TB -- host directed therapy -- M.tuberculosis -- inflammation -- Mesenchymal stromal cells -- T-cells -- cancer -- HDT; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2015.01.016
• Languages: English
• ISSNs: 1201-9712

Abstract

Summary: Cellular therapy now offer promise of potential adjunct therapeutic options for treatment of drug-resistant tuberculosis (TB). We review here the role of Mesenchymal stromal cells, (MSCs), as well as other immune effector cells in the therapy of infectious diseases with a focus on TB. MSCs represent a population of tissue-resident non-hematopoietic adult progenitor cells which home into injured tissues increase the proliferative potential of broncho-alveolar stem cells and restore lung epithelium. MSCs have been shown to be immune-modulatory and anti-inflammatory mediated via cell-cell contacts as well as soluble factors. We discuss the functional profile of MSCs and their potential use for adjunct cellular therapy of multi-drug resistant TB, with the aim of limiting tissue damage, and to convert unproductive inflammatory responses into effective anti-pathogen directed immune responses. Adjunct cellular therapy could potentially offer salvage therapy options for patients with drug-resistant TB, increase clinically relevant anti- M.tuberculosis directed immune responses and possibly shorten the duration of anti-TB therapy.